931PCLINICAL OUTCOME IN PATIENTS WITH PRIMARY ADVANCED OR METASTATIC ENDOMETRIAL CARCINOMA TREATED WITH STANDARD CHEMOTHERAPY REGIMEN ACCORDING DIFFERENT HISTOPATHOLOGIC CHARACTERISTICS.

M. Milović,D. Gavrilovic,L. Stamatović
DOI: https://doi.org/10.1093/annonc/mdu338.55
IF: 51.769
2014-09-01
Annals of Oncology
Abstract:ABSTRACT Aim: The aim of this study was to investigate difference in clinical outcome in patients with primary advanced or metastaitic endometrial cancer treated with standard chemotherapy doxorubicin-cisplatin (DOX-CDDP), regarding and focusing on histological subtype. Methods: Eligible patients had histologically-proven advanced and/or metastatic endometrial adenocarcinoma and were chemotherapy-naive. Treatment consisted of CDDP 50 mg/m2 added to DOX 60 mg/m2, every 3 weeks. Kaplan Maier method and Log rank test were used to assess survival prognostic factors. Median age was 64 years (range 34-77). Patients were divided into 2 groups according histopathologic type: Type 1 EC- endometrioid and Type 2 EC- serous/clear cell/ undifferentiated type. Between 2007 and 2012, we analysed 18 patients (60%) with Type 2 EC (6 papillary serous, 11 clear cell, 1 undifferentiated) and 12 patients (40%) with Type 1 EC. Results: FIGO stages were as follows: FIGO III = 18 (60%), FIGO IV = 12 (40%). Response for Type 1 EC was as follows: 12 (100%) patients had partial and complete remission (responders). Response for Type 2 was as follows: 7 patients (39%) had stable disease(SD) and 11 patients (61%) had partial and complete remission (responders).The combination DOX–CDDP provided a significantly greater therapeutic response in Type 1 EC compared to Type 2 EC ( Fischer Exact test; p =0.024). At time of analysis 76% of patients were still alive after median follow up of 21 months (9-58). Median progression free survival (PFS) for Type 1 EC was 18 months (range 8-56). Median progression free survival (PFS) for Type 2 EC was 11 months (5-26), so there was demonstrated significant difference between Type 1 and Type 2 EC according PFS (Log-Rank test; p = 0.0014). It was also shown trend in significance between Type 1 and 2 EC according OS (Log-Rank test; p = 0.062). Conclusions: Type 2 endometrial cancer is rare and differs from Type 1 especially for the high frequency of distant metastasis. Our results indicate that there is demonstrated worse response and outcomes to standard chemotherapy in Type 2 EC compared to Type 1 EC, so multicentric studies are needed to better define appropriate management for these kind of malignancies. Disclosure: All authors have declared no conflicts of interest.
What problem does this paper attempt to address?